Biora Therapeutics Inc. [BIOR] is 37.89% higher this YTD. Is it still time to buy?

Biora Therapeutics Inc. [NASDAQ: BIOR] traded at a high on 01/17/23, posting a 6.32 gain after which it closed the day’ session at $4.54. The company report on January 9, 2023 that Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Company is on track to move into the clinic with its lead targeted therapeutics program.

The results of the trading session contributed to over 5609867 shares changing hands. Over the past one week, the price volatility of Biora Therapeutics Inc. stands at 56.90% while the volatility over the past one month is 25.65%.

The market cap for BIOR stock reached $50.30 million, with 8.93 million shares outstanding and 8.32 million shares in the current float. Compared to the average trading volume of 1.99M shares, BIOR reached a trading volume of 5609867 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Biora Therapeutics Inc. [BIOR]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BIOR shares is $82.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BIOR stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

The Average True Range (ATR) for Biora Therapeutics Inc. is set at 0.98, with the Price to Sales ratio for BIOR stock in the period of the last 12 months amounting to 71.86.

How has BIOR stock performed recently?

Biora Therapeutics Inc. [BIOR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 115.17. With this latest performance, BIOR shares dropped by -0.66% in over the last four-week period, additionally sinking by -73.68% over the last 6 months – not to mention a drop of -88.72% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BIOR stock in for the last two-week period is set at 50.94, with the RSI for the last a single of trading hit 53.55, and the three-weeks RSI is set at 47.83 for Biora Therapeutics Inc. [BIOR]. The present Moving Average for the last 50 days of trading for this stock 5.11, while it was recorded at 5.24 for the last single week of trading, and 14.92 for the last 200 days.

Biora Therapeutics Inc. [BIOR]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Biora Therapeutics Inc. [BIOR] shares currently have an operating margin of -9449.64 and a Gross Margin at -15.24. Biora Therapeutics Inc.’s Net Margin is presently recorded at -14316.04.

Biora Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 1.70.

Insider trade positions for Biora Therapeutics Inc. [BIOR]

There are presently around $9 million, or 24.00% of BIOR stock, in the hands of institutional investors. The top three institutional holders of BIOR stocks are: ATHYRIUM CAPITAL MANAGEMENT, LP with ownership of 1,194,234, which is approximately 0% of the company’s market cap and around 1.90% of the total institutional ownership; NEUBERGER BERMAN GROUP LLC, holding 261,642 shares of the stock with an approximate value of $1.19 million in BIOR stocks shares; and VANGUARD GROUP INC, currently with $1.07 million in BIOR stock with ownership of nearly 3.448% of the company’s market capitalization.

Positions in Biora Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 20 institutional holders increased their position in Biora Therapeutics Inc. [NASDAQ:BIOR] by around 45,562 shares. Additionally, 16 investors decreased positions by around 35,741 shares, while 18 investors held positions by with 1,904,554 shares. The mentioned changes placed institutional holdings at 1,985,857 shares, according to the latest SEC report filing. BIOR stock had 6 new institutional investments in for a total of 33,011 shares, while 9 institutional investors sold positions of 6,854 shares during the same period.


Please enter your comment!
Please enter your name here